Categories: 3DAppCorporateEngineeringFutureHealthTechHumanMedtechSocietyTechnology
九州大学出身の中山功一氏（現 佐賀大学医学部臓器再生医工学講座教授）が発明した、三次元細胞積層技術を用いて、スフェロイドから立体的な組織・臓器（骨軟骨・血管・神経等）を作製し、再生医療等製品の実用化に取り組んでいる九州大学発の再生医療ベンチャーです。
Investors 2
Mentions in press and media 5
| Date | Title | Description |
| 07.07.2025 | C2i and Hitachi Launch First Automated Organoid Culture System in Hong Kong | Hong Kong based Centre for Immunology & Infection Limited (C2i), its spin-off C2iTech, and Japanese multinational conglomerate Hitachi have announced a strategic collaboration to develop 3D printed airway organoids for clinical applicat... |
| 25.03.2022 | Cyfuse Co., Ltd. Business and capital alliance with Fukuoka Jisho Co., Ltd. for the purpose of regional revitalization | Cyfuse Co., Ltd.
About business capital tie-up with Fukuoka Jisho Co., Ltd. for regional revitalization
……………………………………………………………………………………………
Cyfuse Co., Ltd. (Headquarters: Bunkyo-ku, Tokyo, Representative Director: Shizuka Akieda, hereinaft... |
| 29.09.2020 | Yokohama joins Maryland Life Sciences’ Bio Innovation Conference through Kanagawa virtual trade delegation | Three Yokohama-based companies will be participating in this year’s Bio Innovation Conference, hosted by Maryland Life Sciences, a division of the Maryland Tech Council. The startups will be joining through a trade mission sponsored by Kana... |
| 07.09.2016 | This is how 3-D bioprinting companies are transforming drug development | Organovo is the leader in 3-D bioprinting at the moment. The publicly traded San Diego company has been selling 3-D liver tissue to pharma companies for about 18 months and is about to expand into kidney tissue. The goal is to support drug ... |
| - | This is how 3-D bioprinting companies are transforming drug development | Let’s face it, cells generally like having company, forming communities with other cell types to make complete tissues. However, quite often, researchers isolate cells from their 3-D environments, creating 2-D models that don’t always repli... |
Reviews 0
